Skip to content

Study · Observational study · n = 91 · 2022

18 results

PSAT156 Abaloparatide Implementation and Follow-Up: Real-World Results of a Pharmacist-Run Anabolic Osteoporosis Clinic

The source lists no authors.

Journal of the Endocrine Society1 Nov 2022

PMCIDPMC9624828 (opens in a new tab)PepBankPUB-94147142
Read at sourceSource pageAsk about this study
Jump to 18 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study18

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to increased spine T-scores versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to higher spine T-scores than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSpine T-score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  2. 02HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to increased spine BMD versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to higher spine bone density than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSpine BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  3. 03HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to increased total hip T-scores versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to higher total hip T-scores than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip T-score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  4. 04HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to increased total hip BMD versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to higher total hip bone density than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  5. 05HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to increased femoral neck T-scores versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to higher femoral neck T-scores than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck T-score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  6. 06HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to increased femoral neck BMD versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to higher femoral neck bone density than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  7. 07HumanObservational studyEfficacy outcome

    In clinic patients with osteoporosis, abaloparatide treatment was linked to decreased T-scores at the one-third radius versus baseline.

    In plain wordsIn clinic patients, abaloparatide treatment was linked to lower forearm T-scores than at baseline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseOne-third radius T-score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 + 2 months (range 9–18 months)As given in this study (human).

    Source sentences

    Summary
    There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  8. 08HumanObservational studySafety outcome

    In clinic patients receiving abaloparatide, 18 patients discontinued therapy due to an adverse drug reaction.

    In plain wordsIn clinic patients receiving abaloparatide, 18 patients stopped treatment because of an adverse drug reaction.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedDiscontinuation due to adverse drug reaction
    Study

    n = 91

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Discontinuation due to ADR
    18 patients
    patients receiving therapy
    Discontinuation due to ADR
    19.8%
    patients receiving therapy

    Source sentences

    Summary
    Eighteen patients (19.8%) discontinued therapy due to an ADR.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.
  9. 09HumanObservational studyOther

    In the pharmacist-run clinic, patients initiating abaloparatide had a 72.5% persistence rate.

    In plain wordsIn the pharmacist-run clinic, 72.5% of patients who started abaloparatide continued treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedTreatment persistence
    Study

    n = 91

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Measurements

    Persistence rate
    72.5%
    patients initiating abaloparatide

    Source sentences

    Summary
    Noteworthy, however, is the achieved 72.5% persistence rate of the patients initiating abaloparatide at this pharmacist-run anabolic osteoporosis clinic.
    2 context sentences
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

Studies that did not test the peptide alone9

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 10HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, subsequent antiresorptive therapy was linked to increased total hip T-scores.

    In plain wordsIn clinic patients after abaloparatide, later antiresorptive treatment was linked to higher total hip T-scores.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip T-score after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 11HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, subsequent antiresorptive therapy was linked to increased total hip BMD.

    In plain wordsIn clinic patients after abaloparatide, later antiresorptive treatment was linked to higher total hip bone density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  3. 12HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, subsequent antiresorptive therapy was linked to increased lumbar spine T-scores.

    In plain wordsIn clinic patients after abaloparatide, later antiresorptive treatment was linked to higher lower spine T-scores.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine T-score after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  4. 13HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, subsequent antiresorptive therapy was linked to increased lumbar spine BMD.

    In plain wordsIn clinic patients after abaloparatide, later antiresorptive treatment was linked to higher lower spine bone density.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  5. 14HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, femoral neck T-score changes during subsequent antiresorptive therapy were nonsignificant.

    In plain wordsIn clinic patients after abaloparatide, femoral neck T-scores did not change significantly during later antiresorptive treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral neck T-score after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  6. 15HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, femoral neck BMD changes during subsequent antiresorptive therapy were nonsignificant.

    In plain wordsIn clinic patients after abaloparatide, femoral neck bone density did not change significantly during later antiresorptive treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral neck BMD after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  7. 16HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, one-third radius T-score changes during subsequent antiresorptive therapy were nonsignificant.

    In plain wordsIn clinic patients after abaloparatide, forearm T-scores did not change significantly during later antiresorptive treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeOne-third radius T-score after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  8. 17HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In clinic patients previously receiving abaloparatide, one-third radius BMD changes during subsequent antiresorptive therapy were nonsignificant.

    In plain wordsIn clinic patients after abaloparatide, forearm bone density did not change significantly during later antiresorptive treatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeOne-third radius BMD after antiresorptive therapy
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  9. 18HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyEfficacy outcome

    In the abaloparatide clinic cohort, one fracture occurred during the evaluation period encompassing sequential therapy.

    In plain wordsIn the clinic cohort receiving abaloparatide and later treatment, one fracture occurred during evaluation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Direction not reportedFractures during evaluation
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Reported fractures
    1 fracture
    evaluation period

    Source sentences

    Summary
    There was one reported fracture during the evaluation period.
    3 context sentences
    Summary · context
    All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab.
    Summary · context
    To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic.
    Summary · context
    Each patient served as his/her own control.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.